Improving the efficacy of antibody-based cancer therapies

By P. Carter. Nature Reviews. Cancer, 2001

881 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, neutral): “, 2005), which could allow increased temporal control, and we expect that its small size will lead to increased tumor penetration (Carter, 2001).”
scFv Antibody: Principles and Clinical Application (2012, neutral): “The potential targets for immunotherapy could be achieved by identification of tumorspecific or associated antigens on the surface of breast cancer cells [158].”
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 (2003, background): “Furthermore, the therapeutic mAbs were given by a different route (i.p.) to avoid rapid C-mediated lysis of tumor cells in the circulation before their homing into the different organs.”
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (2004, background): “A280 D (280)CDl Ab (280)CAbl (1) 7064 Effect of Drug Loading on ADC Activity”